Core Insights - The article highlights the rise of Fan Daidi and her husband Yan Jianya as the new richest individuals in Shaanxi, with a combined stock value exceeding 45 billion RMB, primarily due to their holdings in Juzhibio and Triangle Defense [1][5]. Company Performance - Juzhibio's market capitalization reached 83.6 billion HKD (approximately 77.3 billion RMB) as of May 12, 2024, while Triangle Defense's market cap was 14.7 billion RMB [1]. - Juzhibio reported a revenue of 5.54 billion RMB in 2024, marking a year-on-year growth of 57.2%, and a net profit of 2.06 billion RMB, up 42.1% from the previous year [7][8]. - Triangle Defense's revenue for the same period was 1.59 billion RMB, with a significant decline of 30.02%, and a net profit of 380 million RMB, down 49.12% [7][9]. Shareholding Structure - Fan Daidi and Yan Jianya hold a combined 57.32% stake in Juzhibio, with Yan Jianya's effective shareholding being 13.77% after considering various entities [1][2]. - The couple's total shareholding value reached 46.3 billion RMB, surpassing other notable wealthy individuals in the region [5]. Historical Context and Growth - Juzhibio has shown remarkable growth since its inception in 2001, becoming the largest collagen-based skincare company in China by 2019 [6]. - The company has experienced substantial revenue growth rates from 2020 to 2024, with annual growth rates of 24.44%, 30.41%, 52.30%, 49.05%, and 57.17% respectively [6]. Research and Development Contributions - Fan Daidi's contributions to the field of biomanufacturing, particularly in the synthesis of complex pharmaceutical molecules, have been pivotal to Juzhibio's success [6].

Group 1 - The core viewpoint of the article highlights the rise of Fan Daidi and her husband Yan Jianya as the new richest individuals in Shaanxi, with a combined stock value of 457 billion yuan from their holdings in Juzi Biotechnology and Triangle Defense [1][2] - Juzi Biotechnology, which specializes in recombinant collagen, has a market capitalization of 836 million HKD (approximately 773 million yuan) as of May 12, while Triangle Defense, a military enterprise, has a market capitalization of 147 million yuan [1][2] - According to the 2024 Hurun Rich List, the couple ranks 196th nationally with a wealth of 245 million yuan, placing them third among the wealthy in Shaanxi [1] Group 2 - Fan Daidi, born in January 1966, has a background in biological engineering and has held various academic positions at Northwest University, including Vice President [2] - In 2000, she developed a type of human-like collagen using genetic engineering technology, and in 2001, she applied for China's first patent for recombinant collagen [2] - Since 2019, Juzi Biotechnology has become the largest collagen professional skincare product company in China and one of the largest globally in terms of recombinant collagen production capacity [2] - In the latest annual report, Juzi Biotechnology reported a revenue of 5.539 billion yuan, a year-on-year increase of 57.2%, and a net profit of 2.062 billion yuan, up 42.1%, with a gross margin of 82.09% [2]

西北大学官网资料显示，范代娣出生于1966年1月，今年59岁，陕西蒲城人，从华东理工大学生物工程 系博士毕业后，便进入西北大学工作，历任西北大学化工学院副院长、院长。今年4月，范代娣出任西 北大学党委委员、常委、副校长。 2000年，范代娣用基因工程技术高密度发酵生产的一种类人胶原蛋白宣告问世。2001年，范代娣申请了 中国第一个重组胶原蛋白发明专利——"一种类人胶原蛋白及其生产方法"。同年9月，范代娣夫妻二人 创立了巨子生物基因技术股份有限公司。 自2019年起，巨子生物成为中国最大的胶原蛋白专业皮肤护理产品公司，也是全球范围内拥有最大重组 胶原蛋白产能的企业之一。2022年11月，该公司在港股上市。 年报显示，去年，巨子生物实现营收55.39亿元，同比增长57.2%；实现归属净利润20.62亿元，同比增 长42.1%，公司毛利率达到82.09%。 今年4月上任的西北大学女副校长范代娣及其丈夫以持股市值超450亿元的身价，成为新一任陕西首富。 目前，范代娣及其丈夫严建亚名下有巨子生物(02367.HK)和三角防务(300775)两家上市公司。截至5月 12日收盘，巨子生物的市值为836亿港元(约合人民币77 ...

- The report predicts adjustments to the sample stocks of seven major broad-based indices in the Chinese market, including CSI 300, CSI 500, SSE 50, STAR 50, STAR 100, ChiNext Index, and ChiNext 50, based on the index compilation rules and data as of April 30, 2025 [1][7] - The CSI 300 Index selects stocks from the Shanghai and Shenzhen markets that meet criteria such as good operational status, no significant financial issues, and no abnormal price fluctuations. The selection process involves ranking stocks by daily average trading volume and market capitalization over the past year, applying buffer rules, and excluding stocks with significant losses or long-term suspensions. Adjustments are limited to 10% of the constituent stocks per review [8] - The CSI 500 Index excludes CSI 300 constituents and follows a similar methodology, focusing on stocks with good operational status, no financial irregularities, and stable price movements. Stocks are ranked by daily average trading volume and market capitalization, with buffer rules applied, and adjustments are capped at 10% of the constituent stocks [10] - The SSE 50 Index is derived from the SSE 180 Index, selecting stocks based on daily average market capitalization and trading volume over the past year. The accuracy of SSE 50 predictions depends on the SSE 180 Index's accuracy. Adjustments are limited to 10% of the constituent stocks [13] - The STAR 50 Index represents the top 50 securities on the STAR Market by market capitalization and liquidity. Stocks are ranked by daily average market capitalization, with buffer rules applied, and adjustments are capped at 10% of the constituent stocks [15] - The STAR 100 Index includes 100 mid-sized securities from the STAR Market, reflecting the performance of mid-cap companies. The selection process is similar to STAR 50, with adjustments limited to 10% of the constituent stocks [17] - The ChiNext Index selects stocks from the ChiNext Board based on the top-ranked daily average market capitalization over the past six months. Buffer rules are applied, and stocks with significant losses or long-term suspensions are excluded. Adjustments are capped at 10% of the constituent stocks [20] - The ChiNext 50 Index selects the most liquid stocks from the ChiNext Index's 100 constituents, considering industry coverage and applying buffer rules. Adjustments are limited to 10% of the constituent stocks [24]

Core Viewpoint - The article discusses the rise of Fan Daidi and her husband Yan Jianya as the new richest couple in Shaanxi, primarily due to their holdings in Juzi Biological and Triangle Defense, with a combined market value of nearly 900 billion yuan [2][9]. Group 1: Personal Background and Wealth - Fan Daidi holds a stock value of 443 billion yuan and has recently become the richest person in Shaanxi [2][5]. - The couple's daughter, Yan Yubo, has been rigorously trained and holds multiple financial certifications, currently serving as the secretary and executive director of Juzi Biological, with a salary increase from 140,000 yuan in 2023 to 360,000 yuan in 2024 [3][16]. Group 2: Company Overview - Juzi Biological - Juzi Biological, a leader in the field of recombinant collagen, has seen its revenue grow from 9 billion yuan in 2019 to 55 billion yuan in 2024, marking a fivefold increase over five years [18]. - The company has a projected revenue of 45.4 billion yuan in 2024, with a year-on-year growth of 62.9%, and a gross margin of 82% [17][21]. - Juzi Biological has raised a total of 45.6 billion yuan through various financing rounds since its IPO in 2022, while distributing 2.3 billion yuan in dividends to the Fan family [25] [24]. Group 3: Company Overview - Triangle Defense - Triangle Defense, which specializes in aerospace and military components, has a market value exceeding 100 billion yuan, with Yan Jianya controlling 16.09% of the shares [26][27]. - The company has experienced significant revenue growth from 4.7 billion yuan in 2018 to 24.9 billion yuan in 2023, but has faced a decline in 2024 due to reduced orders from major clients [28]. - Triangle Defense is currently under regulatory scrutiny for various management issues, which could impact its future performance [28].

证券研究报告·公司点评报告·航空装备Ⅱ 2025 年 05 月 06 日 证券分析师 苏立赞 执业证书：S0600521110001 sulz@dwzq.com.cn 证券分析师 许牧 执业证书：S0600523060002 三角防务（300775） 2024 年报点评：募投项目稳定建设，国产大 飞机有望打开更大空间 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 2,271 | 1,590 | 2,299 | 2,622 | 4,003 | | 同比 | 21.05 | (30.02) | 44.63 | 14.07 | 52.64 | | 归母净利润（百万元） | 747.01 | 380.05 | 571.53 | 697.12 | 974.29 | | 同比 | 19.58 | (49.12) | 50.38 | 21.97 | 39.76 | | EPS-最新摊薄（元/股） | 1.36 | 0.69 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a total revenue of 1.59 billion yuan in 2024, a year-on-year decrease of 30.02%, and a net profit attributable to shareholders of 380 million yuan, down 49.12% year-on-year [1][8] - The decline in revenue and profit is attributed to reduced product delivery quantities and amounts following a concentrated demand release in 2023, along with rising raw material costs and longer production cycles [8] - The company has made significant advancements in technology and product development, including breakthroughs in high-temperature alloy turbine disc forging technology and large-scale titanium alloy rotor systems for helicopters, enhancing its market position in high-end forgings [8] - Future growth is expected to be driven by continued investment in defense equipment, rapid development in aerospace and high-tech industries, and improvements in the company's technology, market, and management capabilities [8] Financial Summary - For 2024, the company achieved total revenue of 1.59 billion yuan, with a projected revenue increase to 2.30 billion yuan in 2025 and 2.62 billion yuan in 2026, reaching 4.00 billion yuan by 2027 [1][9] - The net profit forecast for 2025 is 572 million yuan, increasing to 697 million yuan in 2026 and 974 million yuan in 2027 [1][9] - The earnings per share (EPS) are expected to rise from 0.69 yuan in 2024 to 1.77 yuan in 2027, with corresponding P/E ratios decreasing from 35.76 to 13.95 over the same period [1][9] - The company's total assets are projected to grow from 91.52 billion yuan in 2024 to 158.87 billion yuan in 2027, reflecting ongoing investment in projects and construction [9]

证券代码：300775 证券简称：三角防务 公告编号：2025-065 债券代码：123114 债券简称：三角转债 西安三角防务股份有限公司 第三届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 西安三角防务股份有限公司（以下简称"公司"或"本公司"） 于2025年4月30日向全体董事发出召开第三届董事会第二十五次会议 的通知。会议于2025年5月6日在公司会议室以现场和通讯相结合的方 式召开。本次会议应出席董事9名，实际出席董事9名。会议由董事长 严建亚先生主持，公司部分监事和高级管理人员列席本次会议。本次 会议的召开符合《中华人民共和国公司法》等法律法规、规范性文件 和《公司章程》的规定。 董事会 2025 年 5 月 6 日 1．审议通过《关于聘任公司副总经理、财务总监、董事会秘书的 议案》 表决结果：9票同意，0票反对，0票弃权。本议案获得通过。 具 体 内 容 详 见 公 司 2025 年 5 月 6 日 刊 载 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn)的相关公 ...

西安三角防务股份有限公司 关于聘任公司副总经理、财务总监、董事会秘书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 西安三角防务股份有限公司（以下简称"公司"）于 2025 年 5 月 6 日召开第三届董事会第二十五次会议，审议通过了《关于聘任公司 副总经理、财务总监、董事会秘书的议案》，现将具体情况公告如下： 一、董事会秘书辞职的情况 公司董事会于近日收到董事会秘书刘家骏先生的书面辞职报告， 因个人原因，刘家骏先生申请辞去公司第三届董事会秘书职务（原定 任期届满日为 2025 年 9 月 21 日）。辞去上述职务后，刘家骏先生将 不再担任公司任何职务。根据相关法律法规、规范性文件以及《公司 章程》等相关规定，刘家骏先生的辞职申请自送达董事会之日起生效。 刘家骏先生在担任公司董事会秘书期间勤勉尽责，为促进公司健 康稳定发展发挥了积极作用，公司及董事会对其任职期间为公司发展 作出的贡献表示衷心感谢。 另外，因公司战略发展需要以及工作安排的调整，严健先生申请 证券代码：300775 证券简称：三角防务 公告编号：2025-066 债券代码：123114 债 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - The company reported a revenue of 1.59 billion in 2024, a year-on-year decrease of 30.02%, and a net profit attributable to shareholders of 380 million, down 49.12% year-on-year [2][5]. - In Q4 2024, the company achieved a revenue of 227 million, a year-on-year decrease of 29.8%, but a quarter-on-quarter increase of 382.99% in net profit [2][5]. - For Q1 2025, the company reported a revenue of 403 million, a year-on-year decrease of 21.07%, with a net profit of 129 million, down 22.92% year-on-year [2][5]. - The company signed contracts worth approximately 875.34 million (including tax) in April 2025, which is expected to positively impact its performance for the year [11]. Summary by Sections Financial Performance - 2024 total revenue was 1.59 billion, with a gross profit margin of 34.44%, down 9.05 percentage points year-on-year [11]. - Q4 2024 gross profit margin was 47.75%, up 0.72 percentage points year-on-year and up 51.52% quarter-on-quarter [11]. - Q1 2025 gross profit margin was 42.75%, up 0.43 percentage points year-on-year [11]. Business Development - The company is actively expanding new production capacity and business lines, with construction projects totaling 1.018 billion at the end of Q1 2025, a 3% increase from the beginning of the year [11]. - The company is conducting feasibility studies for new business opportunities, particularly in the aircraft assembly sector, which may benefit from the delivery of domestically produced large aircraft [11]. Profit Forecast - The company is expected to achieve net profits of 606 million, 831 million, and 998 million for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 59%, 37%, and 20% [11].